Long-term survival in a patient with metastatic squamous cell lung carcinoma: A case report

Barletta,Emiddio; Federico,Piera; Tinessa,Vincenza; Germano,Domenico; Cannella,Lucia; Pironti,Teresa; Daniele,Bruno

doi:10.3892/mco.2017.1408

Long-term survival in a patient with metastatic squamous cell lung carcinoma: A case report

Authors:
- Emiddio Barletta
- Piera Federico
- Vincenza Tinessa
- Domenico Germano
- Lucia Cannella
- Teresa Pironti
- Bruno Daniele
View Affiliations

Affiliations: Division of Medical Oncology, ‘G. Rummo’ Hospital, I-82100 Benevento, Italy, Department of Radiotherapy, ‘G. Rummo’ Hospital, I-82100 Benevento, Italy
Published online on: September 1, 2017 https://doi.org/10.3892/mco.2017.1408
Pages: 928-930

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non-small-cell lung cancer (NSCLC) is the most common malignancy in industrialized countries, with a 5-year survival rate of only ~15%, as the majority of the patients have advanced-stage disease at diagnosis and the treatment options are limited. Squamous cell carcinoma the second most frequent type of NSCLC and is closely associated with cigarette smoking. We herein present the case of a 72-year-old male smoker, diagnosed with stage IV squamous cell lung carcinoma, with a solitary brain metastasis. After the diagnosis, stereotactic radiotherapy was performed on the brain metastasis. Following radiotherapy, chemotherapy with carboplatin + paclitaxel was initiated. However, after 2 cycles of chemotherapy, disease progression in the lung was observed. Therefore, second-line treatment with pemetrexed was started, which was discontinued after 2 cycles due to further disease progression. Third-line treatment with erlotinib was then administered, with notable benefit, as the patient remains alive after 6 years of treatment with a good performance status. The mutation status of EGFR was unknown.

View Figures

View References

1	Jemal A, Bray E, Center M, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F and Capocaccia R: EUROCARE Working Group. EUROCARE-4: Survival of cancer patients diagnosed in 1995–1999. Results and commentary. Eur J Cancer. 45:931–91. 2009. View Article : Google Scholar : PubMed/NCBI
3	Spiro SG and Silvestri GA: Oive hundred years of lung cancer. Am J Respir Crit Care Med. 172:523–529. 2005. View Article : Google Scholar : PubMed/NCBI
4	Youlden DR, Cramb SM and Baade PD: The International epidemiology of lung cancer: Geographical distribution and secural trends. J Thorac Oncol. 3:818–831. 2008. View Article : Google Scholar
5	Alberg AJ and Samet JM: Epidemiology of lung cancer. Chest. 123 (1 Suppl):S21–S49. 2003. View Article : Google Scholar
6	Shepherd FA, Pereira Rodrigues J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 353:123–132. 2005. View Article : Google Scholar : PubMed/NCBI
7	Neal JW: The SATURN trial: The value of maintenance erlotinib in patients with non-small-cell lung cancer. Future Oncol. 6:1827–1832. 2010. View Article : Google Scholar : PubMed/NCBI
8	Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, Johannsdottir HK, Klughammer B and Gonzalez EE: Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): A randomized multicentre, open-label, phase 3 study. Lancet Oncol. 13:300–308. 2012. View Article : Google Scholar : PubMed/NCBI
9	Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, et al: Erlotinib versus standard chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomized phase 3 study. Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
10	Johnson BE and Jänne PA: Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res. 65:7525–7529. 2005. View Article : Google Scholar : PubMed/NCBI
11	Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, et al: Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 12:3908–3914. 2006. View Article : Google Scholar : PubMed/NCBI
12	Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open label, randomised, phase 3 study. Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
13	Popat S, Hughes S, Papadopoulos P, Wilkins A, Moore S, Priest K, Meehan L, Norton A and O'Brien M: Recurrent responses to non-small cell lung cancer brain metastases with erlotinib. Lung Cancer. 56:135–137. 2007. View Article : Google Scholar : PubMed/NCBI
14	Grace Li: TLCR is endorsed by the Spanish Lung Cancer Group (SLCG): New horizons for strong academic collaboration in lung cancer. J Thorac Dis. Dec 5;E217–E218. 2013.PubMed/NCBI
15	Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, et al: Erlotinib versus standard chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomized phase 3 study. Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI